Clinical trial · Interventional
Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope
Collecting Spectral Signatures of Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Benign Lesions and Normal Tissues Using Spectra-Scope
NCT03069846CI-TRIAL-00032608unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is to collect emission spectra of normal tissue, pigmented normal lesion, benign lesion, SCC, BCC and melanoma to construct the database and validate the classifying algorithm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Spectra-Scope | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Measurement using Spectra-Scope
- description
- Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
- interventionNames
- Device: Spectra-Scope
Primary outcomes (1)
- measure
- The primary endpoint is to compare the aggregated emission spectra of skin cell carcinoma verses normal skin.
- timeFrame
- We plan to recruit 150 patients within a 3 month time frame.
- description
- The aggregated emission spectra collected over a range of wavelengths from skin cells (skin cancer verses normal skin) irradiated with a commercial laser will be plotted to identify wavelengths with greatest spectra seperation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Be aged 18 years or over; 2. Have at least one suspicious lesion that: 1. Is required to be biopsied for assessment of skin cancer (as assessed by at least one dermatologist); 2. Has a diameter of more than 2 mm but less than 22 mm; 3. Is accessible to the Spectra-Scope device; 3. Provide written informed consent. Exclusion Criteria: 1. Have a known allergy to ethanol; 2. Have a lesion that: 1. Has previously been biopsied, excised or traumatised; 2. Is not intact; 3. Is within 1 cm of the eye; 4. Is on a mucosal surface (lips, genitals); 5. Is on palmar hands; 6. Is on palmar feet; 7. Is on or under nails; 8. Is located on or in an area of visible scarring; 9. Contains foreign matter (tattoo, splinter, marker) 3. Have an active infection; 4. Have an open lesion sampled; 5. Have an autoimmune disease such as lupus or scleroderma vitiligo.
References
Publications (0)
Data not yet available
No reference posted for this study.